Related Experiment Video
Updated: Nov 19, 2025
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
23.8K
Botulinum toxin in treating Hailey-Hailey disease: A systematic review
Hanlin Zhang1, Keyun Tang1, Yuchen Wang1
1Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Journal of Cosmetic Dermatology
|February 3, 2021
Summary
Botulinum toxin shows promise for treating Hailey-Hailey disease, offering partial or complete remission with no reported side effects. It is recommended as an adjuvant therapy for severe cases.
Area of Science:
- Dermatology
- Medical Research
Background:
- Hailey-Hailey disease is a rare, recurrent blistering disorder affecting intertriginous areas.
- Botulinum toxin is an emerging treatment for this condition.
Purpose of the Study:
- To systematically review and evaluate the efficacy and safety of botulinum toxin for Hailey-Hailey disease treatment.
Main Methods:
- A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and Web of Science.
- Search terms included variations of 'Hailey-Hailey disease' and 'botulinum toxin'.
Main Results:
- Sixteen articles involving 38 patients demonstrated significant efficacy, with most achieving partial or complete remission.
- No adverse effects were reported in patients treated with botulinum toxin.
- Previous treatments with botulinum toxin in other studies showed limited success in 10 patients.
Conclusions:
- Botulinum toxin is a promising alternative treatment for severe and recalcitrant Hailey-Hailey disease.
- It is recommended as an adjuvant or supplemental therapy.
- Further large-scale studies are needed to confirm efficacy, safety, and cost-effectiveness.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
924
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
924
01:31Skeletal Muscle Relaxants: Therapeutic Uses
747
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
747
01:20Myasthenia Gravis: Overview and Treatment
2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
01:28Classification of Skeletal Muscle Relaxants
2.8K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
01:19Depolarizing Blockers: Pharmocokinetics
469
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
469
01:21Skeletal Muscle Relaxants: Adverse Effects
621
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
621